Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 173

Results For "NDA"

4491 News Found

Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Clinical Trials | September 03, 2024

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities


Govt. to improve availability of infrastructure and trained manpower for organ transplantation
News | September 01, 2024

Govt. to improve availability of infrastructure and trained manpower for organ transplantation

Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country


Biocon Pharma receives USFDA approval for daptomycin
Drug Approval | September 01, 2024

Biocon Pharma receives USFDA approval for daptomycin

The approval further adds to Biocon’s portfolio of complex drug products


Natco Pharma announces submission of TABRECTA to USFDA
Drug Approval | August 30, 2024

Natco Pharma announces submission of TABRECTA to USFDA

TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA


Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
News | August 30, 2024

Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split

The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector


Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study
News | August 30, 2024

Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study

The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention


Suven Life Sciences announces FDA acceptance of investigational new drug
Drug Approval | August 30, 2024

Suven Life Sciences announces FDA acceptance of investigational new drug

First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects


Bayer starts Phase III trial in non-small cell lung cancer
Clinical Trials | August 30, 2024

Bayer starts Phase III trial in non-small cell lung cancer

First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations